Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49

Biochemical and Biophysical Research Communications
Uwe A WittelSurinder K Batra


For the therapy of solid tumors, co-administration of angiotensin II (AngII) results in an increased uptake of drugs into the tumor interstitium. We have engineered a dimeric sc(Fv)(2)-AngII fusion construct that combines the superior kinetics of covalent dimeric scFvs [sc(Fv)(2)], recognizing the pancarcinoma tumor-associated antigen 72 (TAG-72), with the advantageous intrinsic activity of AngII. The binding characteristics of the fusion construct were unaltered by the addition of the AngII sequence [affinity constant K(A) 1.18 x 10(7) and 8.42 x 10(6) M(-1) for sc(Fv)(2) and sc(Fv)(2)-AngII, respectively]. The binding of the fusion construct to the angiotensin receptor (AT(1)) was similar to AngII, and the arterial contraction was 16 +/- 1% of the response observed with norepinephrine. In animal studies, the radiolabeled sc(Fv)(2)-AngII construct exhibited similar uptake and a more homogeneous distribution within the tumor as compared to sc(Fv)(2).


Mar 21, 1991·Journal of Immunological Methods·A Larsson, B Axelsson
Jul 18, 1990·Journal of the National Cancer Institute·D ColcherJ Schlom
Aug 1, 1988·European Journal of Cancer & Clinical Oncology·M A BurtonA Coletti
Jan 1, 1984·Cancer Metastasis Reviews·M SuzukiH Sato
Jul 1, 1994·Scientific American·R K Jain
Nov 1, 1993·Computerized Medical Imaging and Graphics : the Official Journal of the Computerized Medical Imaging Society·N TomuraM Kowada
Jan 1, 1996·Annual Review of Immunology·G R ThrushE S Vitetta
May 22, 1998·Journal of Cardiovascular Pharmacology·M KohzukiT Sato
Jul 27, 2001·Cancer Biotherapy & Radiopharmaceuticals·S K Imam
Apr 27, 2002·Science·Timothy P PaderaRakesh K Jain
May 11, 2002·Nature Reviews. Cancer·Rakesh K JainDai Fukumura

❮ Previous
Next ❯


Sep 27, 2006·Cancer Biotherapy & Radiopharmaceuticals·Huguette Albrecht, Sally J DeNardo
Mar 27, 2010·Journal of Biomedicine & Biotechnology·Qiang TongGuo-Bin Wang
May 22, 2007·Trends in Biotechnology·Maneesh JainSurinder K Batra
Jan 9, 2019·Cancer Metastasis Reviews·Rakesh BhatiaSurinder K Batra
Nov 28, 2006·Journal of Molecular Recognition : JMR·Rebecca L Rich, David G Myszka
Feb 21, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maneesh JainSurinder K Batra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biosensors for Cancer Detection

Biosensors are devices that are designed to detect a specific biological analyte by essentially converting a biological entity (ie, protein, DNA, RNA) into an electrical signal that can be detected and analyzed. The use of biosensors in cancer detection and monitoring holds vast potential. Biosensors can be designed to detect emerging cancer biomarkers and to determine drug effectiveness at various target sites. Biosensor technology has the potential to provide fast and accurate detection, reliable imaging of cancer cells, and monitoring of angiogenesis and cancer metastasis, and the ability to determine the effectiveness of anticancer chemotherapy agents.